Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines

Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines

名古屋大学博士学位論文学位の種類:博士(医学) 学位授与年月日:2014-01-31

Bibliographic Details
Main Authors:	大島, 由記子, Oshima, Yukiko
Language:	en
Published:	2014
Online Access:	http://hdl.handle.net/2237/19770

Similar Items

A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
by: Gang Ning, et al.
Published: (2021-08-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
by: Xiao-Dong Jiao, et al.
Published: (2018-02-01)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
by: Trevor Dennie
Published: (2015-01-01)

Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
by: Ariel Hammerman, et al.
Published: (2015-01-01)

Lapatinib, trastuzumab or the combination added to neoadjuvant chemotherapy for breast cancer
by: Quan Liang, et al.
Published: (2016-10-01)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
by: María Luque-Cabal, et al.
Published: (2016-03-01)

Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
by: Maria Luque-Cabal, et al.
Published: (2016-01-01)

Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report
by: Valentina Magri, et al.
Published: (2018-10-01)

Response and resistance to lapatinib in HER2-overexpressing breast cancer
by: Leung, Wing Yin
Published: (2014)

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
by: Fan Yang, et al.
Published: (2020-03-01)

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
by: Lauren Ogawa, et al.
Published: (2018-12-01)

The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
by: Chen ZL, et al.
Published: (2016-05-01)

In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
by: Christel Larbouret, et al.
Published: (2012-02-01)

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib.
by: Loral E Showalter, et al.
Published: (2019-01-01)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.
by: Sharad Verma, et al.
Published: (2018-01-01)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
by: Stefania Gori, et al.
Published: (2016-01-01)

Lapatinib for HER2 overexpressing breast cancer
by: Jones, Jeremy, et al.
Published: (2009)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
by: Hye Jin Lee, et al.
Published: (2020-09-01)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
by: Tejal A. Patel, et al.
Published: (2019-09-01)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
by: Yi Li, et al.
Published: (2020-03-01)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
by: Daisuke Kotani, et al.
Published: (2021-01-01)

Proteasome inhibitors overcome lapatinib resistance through lysosomal degradation of HER family
by: Chi-Hua Tsai, et al.
Published: (2014)

Role of yes-associated protein in resistance of HER2+ breast cancer to lapatinib
by: CHEN Peng, et al.
Published: (2020-04-01)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
by: Min Ye, et al.
Published: (2021-07-01)

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
by: Shao Zhimin, et al.
Published: (2011-06-01)

Lapatinib and capecitabine efficacy at systemic and encephalic level in a patient progressed after dual block of HER2 by trastuzumab and pertuzumab and after T-DM1
by: Andrea Fontana
Published: (2018-06-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Lapatinib for the treatment of HER2-overexpressing breast cancer
by: J Jones, et al.
Published: (2009-10-01)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
by: Andrea L. A. Wong, et al.
Published: (2012-01-01)

Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
by: Lin Shen
Published: (2018-12-01)

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
by: Sara A. Hurvitz, et al.
Published: (2020-11-01)

Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis
by: Muhammad Khan, et al.
Published: (2020-11-01)

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy
by: Eugene R. Ahn, et al.
Published: (2012-11-01)

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues regarding Dual HER2-Targeted Therapy
by: Eugene R. Ahn, et al.
Published: (2012-01-01)

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
by: Armstrong, A., et al.
Published: (2022)